Our Mission
Advanced Solutions Life Sciences (ASLS) is a pioneering leader in the development of cutting-edge solutions at the intersection of biomedical and biotechnology sciences. Specializing in integrated software, hardware, and biological innovations, ASLS is transforming industries with its advanced technology platforms and comprehensive service offerings.
Our flagship products include the patented BioAssemblyBot® 3D Biofabrication Technology Platforms, the robust TSIM® and BioApp® Software, and the innovative, patented VIPM™. These are complemented by a full spectrum of professional services and high-quality supplies to meet the needs of diverse scientific and industrial applications.
Headquartered in a state-of-the-art 15,000-square-foot facility in Louisville, Kentucky, ASLS is a subsidiary of Advanced Solutions, Inc. (ASI), a company with over 30 years of excellence in engineering and innovation. The facility houses a multidisciplinary team of more than 50 highly skilled engineers and technical professionals - including experts in systems, software, mechanical, electrical, and bioengineering. Each project is supported by a dedicated team tailored to its specific technical requirements, ensuring unparalleled expertise and innovation.
At ASLS, we are committed to driving progress through collaboration and innovation, empowering our partners to achieve groundbreaking advancements in life sciences and beyond.
Our Perspective: Biofabrication in a Changing World
1)
We live in the greatest time in human history.
Exponential advancements in biology and intelligent automation have progressed to the level that we now can drastically improve our ability to solve some of the most difficult disease and damaged organs that have relentlessly plagued humanity.
2)
The BioAssemblyBot is a profound & positive platform which brings agile, intelligent automation to some of the brightest scientists and clinicians.
Enabling new advances in science for therapeutics with a focus on curative solutions for diseased or damaged human tissues. This technology is designed to accelerate benchtop-to-bedside development of regenerative medicine therapies.
3)
The biggest challenge facing tissue engineers today is the difficulty of building a robust, adaptable, and perfusable vasculature to nourish living tissue.
Angiomics gives users the ability to incorporate a dynamic, native vascular system in their fabrication strategy to build prevascularized 3D tissues and tissue products.